BioCentury
ARTICLE | Company News

Macrocure plunges on Phase III futility analysis

August 21, 2015 1:09 AM UTC

Macrocure Ltd. (NASDAQ:MCUR) lost $9.07 (75%) to $2.98 on Thursday following its disclosure after market on Wednesday that a futility analysis showed CureXcell was unlikely to meet the primary endpoin...